23andMe

#Healthin2Point00, Episode 217 | 23andMe goes public, & funding for Zus, Pill Club, and Brightline

Today on Health in 2 Point 00, I haven ‘t been fired yet – so I’m taking over this episode. On Episode 217, there’s been a lot going on in the digital health world, including the biggest IPO in health tech ever with Bright Health’s $14 billion valuation. Speaking of IPOs, 23andMe went public yesterday …

#Healthin2Point00, Episode 217 | 23andMe goes public, & funding for Zus, Pill Club, and Brightline Read More »

Seqster bags $12m funding for patient data platform

Digital health player Seqster has raised $12 million in first-round financing that will be used to develop its data platform, which aims to put all a patient’s medical history in one easily-accessible place.  The Series A was led by OmniHealth Holdings, with repeat investor Takeda and Anne Wojcicki – chief executive and founder of genetic …

Seqster bags $12m funding for patient data platform Read More »

PharmaShots Weekly Snapshot (Feb 01-05, 2021)

Reistone Report Results for SHR0302 in P-II Study to Treat Ulcerative Colitis Published: Feb 5, 2020 | Tags: Reiston, Report, Result, SHR0302, P-II, Study, Treat, Ulcerative Colitis Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India Published: Feb 5, 2020 | Tags: Enzene, Receives, Marketing Authorization, Teriparatide (biosimilar), India Johnson & Johnson Reports EUA Submission …

PharmaShots Weekly Snapshot (Feb 01-05, 2021) Read More »

23andMe goes public using Richard Branson’s blank cheque company

DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. The agreement with Branson’s VG Acquisition Corp ties in with an emerging trend among life sciences companies to forego the usual initial public offering (IPO) …

23andMe goes public using Richard Branson’s blank cheque company Read More »

23andMe Going Public Via Virgin Group SPAC Merger

Shots: 23andMe signs a SPAC merger with VGAC for an enterprise value of ~$3.5B, including $509M in cash in trust account and $250M PIPE of common stock at $10.00/share If no public shareholders of VGAC exercise their redemption rights, 23andMe will be capitalized up to $984M in cash to fund operations & support growth initiatives. …

23andMe Going Public Via Virgin Group SPAC Merger Read More »